Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23223779 | 0.91 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL23203059 | 0.89 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3HTR1A | |
| Trifluoroacetic Acid SCHEMBL23203193 | 0.88 | PPARG (0.37) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23223655 | 0.79 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR1ANPY5R | |
| Hydrochloric Acid SCHEMBL23203164 | 0.78 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HTR1ANPY5R | |
| Trifluoroacetic Acid SCHEMBL23467099 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8271672 | 0.76 | SLC6A4 (0.40) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL23203050 | 0.75 | MGLL (0.40) | GRM5 | |
| Hydrochloric Acid SCHEMBL4126360 | 0.74 | SLC6A4 (0.39) | SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL20757563 | 0.71 | LIPG (0.36) | SLC6A2SLC6A4SLC6A3NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097700-A1 | AZETIDINE SULFONAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4082611-A1 | AZETIDINE SULFONAMIDE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20210238136-A1 | AZETIDINE DERIVATIVE, AND PRODRUG THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-08-05 | — | — | US | disclosed |
| WO-2021112251-A1 | AZETIDINE SULFONAMIDE COMPOUND | 第一三共株式会社 | 2021-06-10 | — | — | WO | disclosed |
| EP-3805203-A1 | AZETIDINE DERIVATIVE, AND PRODRUG THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238136-A1 | AZETIDINE DERIVATIVE, AND PRODRUG THEREOF | IFNG, IFNAR1, TLR9 | SLC6A2 344/4885SLC6A4 1304/4885SLC6A3 279/4885 |
| US-20230097700-A1 | AZETIDINE SULFONAMIDE COMPOUND | IFNG, IFNAR1, STAT1 | SLC6A2 414/4885SLC6A4 545/4885SLC6A3 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.